Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001864 · ClinicalTrials.gov registry record · Phase 3
Amblyopia (Lazy Eye) Treatment Study
A Phase 3 study of Amblyopia and Strabismus, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00001864 is a Phase 3 study of Amblyopia and Strabismus that has completed, run by National Eye Institute (NEI). The registered enrollment target is 20 participants, below the 165-participant average among 24 other Amblyopia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001864, a Phase 3 study of Amblyopia and Strabismus, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the results of two standard treatments for amblyopia in order to find out if one is more effective than the other. Amblyopia, which develops in childhood, is also called "lazy eye," because one eye is not being used properly. The brain favors the other eye for some reason, such as crossing or turning out of the eyes, and vision in the weak eye is reduced. Amblyopia is treated by forcing the child to use the weak eye. There are two ways to do this: 1) a patch placed over the "good" eye forces the child to use the weak eye; or 2) an eye drop placed in the "good" eye once a day to blur vision in that eye makes the child rely on the weak eye. The success rates with both of these methods have been reported to be about the same; this study will try to identify if one is more effective than the other. Children will be randomly assigned by computer to one of the following two treatment methods: Patch The child initially will wear a patch over the "good" eye for 8 to 12 hours every day. If vision in the weak eye improves, the patching time will be decreased. If vision remains good after 3 months, the patching will be stopped, unless the child's doctor believes treatment should continue. If vision in the weak eye does not improve, the patching time will be increased. Eye Drops The child will be given one drop per day of atropine in the "good" eye. If vision in the weak eye improves, the drops will be given less often. If the vision remains good after 3 months, the drops will be stopped, unless the child's doctor believes treatment should continue. If the initial daily drop does not improve the vision in the weak eye, the child's eyeglasses may be changed to try to further blur the vision in the "good" eye. After 6 months, treatment may be stopped if it has not been successful. If treatment has been successful after 6 months, it may be continued at a reduced amount or stopped. Follow-up visits will be scheduled every 4 weeks for
Conditions Studied
Interventions
- DRUG Atropine
- DEVICE Patch
Study Locations (1)
Maryland
- National Eye Institute (NEI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1999-05 |
| Est. Completion | 2001-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001864
The ClinicalTrials.gov registry entry for NCT00001864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 24 other Amblyopia trials with a reported enrollment target (88% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Amblyopia appearing as the primary indexed condition, and to 2 interventions - of which Atropine is the first listed.
NCT00001864 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001864 about?
NCT00001864 is a clinical study titled "Amblyopia (Lazy Eye) Treatment Study". The purpose of this study is to compare the results of two standard treatments for amblyopia in order to find out if one is more effective than the other. Amblyopia, which develops in childhood, is also called "lazy eye," because one eye is not being used properly. The brain favors the other eye for...
What is the current status of trial NCT00001864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 1999-05. Estimated completion is 2001-11.
What conditions does trial NCT00001864 study?
This clinical trial studies the following conditions: Amblyopia, Strabismus, Anisometropia.
What interventions are being tested in trial NCT00001864?
The interventions under investigation include: Atropine (DRUG), Patch (DEVICE).
Who is sponsoring clinical trial NCT00001864?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001864 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RECRUITING · Phase 3
-
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
COMPLETED · Phase 3
-
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
COMPLETED · Phase 3
-
Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.